| 1 |
34481017 | Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. | 2022 Feb 1 |
1 |
| 2 |
34797506 | Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. | 2022 Jan |
1 |
| 3 |
34916086 | Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. | 2022 Feb |
2 |
| 4 |
35343252 | Absolute Prostate Specific Antigen after 6 Months of Androgen Deprivation Therapy Is a Predictor of Overall and Cancer-Specific Mortality in Men with Hormone-Sensitive Prostate Cancer. | 2022 Mar 28 |
1 |
| 5 |
35475157 | Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study. | 2022 Jan |
1 |
| 6 |
35616109 | Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy. | 2022 May 2 |
1 |
| 7 |
32504685 | Skene's Gland Adenocarcinoma: Borrowing From Prostate Cancer Experience for the Evaluation and Management of a Rare Malignancy. | 2021 May |
1 |
| 8 |
33713196 | Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan. | 2021 Mar 13 |
1 |
| 9 |
33908799 | Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. | 2021 Sep |
1 |
| 10 |
34176768 | Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. | 2021 Jun 24 |
4 |
| 11 |
34184929 | Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. | 2021 Nov |
2 |
| 12 |
34506516 | Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy. | 2021 |
3 |
| 13 |
34536949 | Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. | 2021 Nov |
6 |
| 14 |
31899823 | Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. | 2020 Mar |
3 |
| 15 |
32606932 | Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer. | 2020 |
2 |
| 16 |
32630494 | Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group. | 2020 Jun 25 |
2 |
| 17 |
32976179 | Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate. | 2020 Dec 1 |
1 |
| 18 |
30703190 | Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. | 2019 May 1 |
2 |
| 19 |
31025578 | Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients. | 2019 Jul |
2 |
| 20 |
31098427 | Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study. | 2019 May |
1 |
| 21 |
31294484 | Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis. | 2019 Sep |
1 |
| 22 |
31329516 | ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. | 2019 Nov 10 |
1 |
| 23 |
31389628 | Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. | 2019 Sep |
2 |
| 24 |
31462169 | Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures. | 2019 Jan 1 |
2 |
| 25 |
31484364 | Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration. | 2019 Sep 3 |
1 |
| 26 |
29151227 | Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer. | 2018 Apr |
2 |
| 27 |
29229176 | Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. | 2018 Apr |
2 |
| 28 |
29243074 | Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy. | 2018 Aug |
1 |
| 29 |
29261442 | Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. | 2018 Feb 1 |
3 |
| 30 |
29383406 | Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. | 2018 Jul |
1 |
| 31 |
29735818 | Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy. | 2018 Sep-Oct |
1 |
| 32 |
29987912 | Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. | 2018 Jul 10 |
2 |
| 33 |
30015690 | Management of nonmetastatic castration-resistant prostate cancer. | 2018 Sep |
1 |
| 34 |
30140660 | Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone. | 2018 Sep |
1 |
| 35 |
30214732 | Incidental discovery of mucinous adenocarcinoma of the prostate following transurethral resection of the prostate: A report of two cases and a literature review. | 2018 Oct |
2 |
| 36 |
30470253 | Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01). | 2018 Nov 23 |
1 |
| 37 |
30567361 | The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients. | 2018 Dec 18 |
1 |
| 38 |
25891393 | Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. | 2017 Jan |
4 |
| 39 |
26585698 | Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy. | 2017 Jan-Feb |
1 |
| 40 |
27837416 | A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy. | 2017 Jan |
1 |
| 41 |
28352622 | Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer. | 2017 Mar |
1 |
| 42 |
28358937 | Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. | 2017 Nov 9 |
1 |
| 43 |
28434181 | Management Options for Biochemically Recurrent Prostate Cancer. | 2017 May |
2 |
| 44 |
28540788 | Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients. | 2017 Nov |
1 |
| 45 |
28816284 | [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy]. | 2017 Aug 18 |
1 |
| 46 |
29212868 | Painful testicular metastasis from prostate adenocarcinoma. | 2017 Dec 5 |
2 |
| 47 |
26641067 | Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer. | 2016 Mar |
5 |
| 48 |
26805930 | Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. | 2016 Dec |
1 |
| 49 |
27325855 | Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. | 2016 Aug 20 |
1 |
| 50 |
27843596 | International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. | 2016 |
2 |